CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...